Effect of cyproterone acetate on active and inactive renin secretion in patients with precocious puberty and genetic short stature.
To evaluate the effect of cyproterone acetate (CA) on the renin-angiotensin-aldosterone axis, we measured the plasma active, inactive and total renin concentrations (PARC, PIRC and PTRC) during and after CA treatment in patients with precocious puberty and genetic short stature. CA was administered at a daily dose of 150-170 mg/m2 in all subjects. PARC and PTRC were measured by immunoradiometric assays. During CA treatment, PARC, PIRC, PTRC and the PARC/PTRC ratio were significantly decreased. The plasma renin activity, measured by enzymatic assay, and the plasma aldosterone concentration were also decreased. After CA discontinuation, all of these were increased immediately along normal ranges. PARC closely correlated with plasma renin activity. These results suggest that CA produces mineralocorticoid action and suppresses the production and activation of renin.
Ohyama
K
K
Department of Pediatrics, Yamanashi Medical College, Japan.
Fujimoto
M
M
Nakagomi
Y
Y
Ohta
M
M
Yamori
T
T
Kato
K
K
D000726:Androgen Antagonists / Q000627:therapeutic use; D002648:Child; D003534:Cyproterone / Q000009:adverse effects / Q000031:analogs & derivatives*; D017373:Cyproterone Acetate; D004792:Enzyme Precursors / Q000378:metabolism; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D006801:Humans; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000503:physiopathology; D012083:Renin / Q000378:metabolism*; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology
D000726:Androgen Antagonists; D004792:Enzyme Precursors; D017373:Cyproterone Acetate; D003534:Cyproterone; D012083:Renin